ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine)

Treatment for Hodgkin Lymphoma

Typical Dosage: Standardized regimen (e.g., Doxorubicin 25mg/m2, Bleomycin 10mg/m2, Vinblastine 6mg/m2, Dacarbazine 375mg/m2, on days 1 & 15 of 28-day cycles)

Effectiveness
85%
Safety Score
25%
Clinical Trials
48
Participants
75K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standardized regimen (e.g., Doxorubicin 25mg/m2, Bleomycin 10mg/m2, Vinblastine 6mg/m2, Dacarbazine 375mg/m2, on days 1 & 15 of 28-day cycles)
Time to Effect
Weeks to months
Treatment Duration
4-6 months
Evidence Quality
HIGH
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$10,000
Side Effect Mgmt:$7,500
Total Annual:$29,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
25
Outcome-Based Costs
Cost per Responder
$34,706
Cost per Remission
$39,333
ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) Outcomes

for Hodgkin Lymphoma

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+75%
Common Side Effects
Nausea/Vomiting
+80%
Hair Loss
+100%
Fatigue
+75%
Neutropenia
+60%
Bleomycin-induced Lung Toxicity
+10%
Cardiotoxicity (Doxorubicin)
+5%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) in Hodgkin Lymphoma

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

NCT04638790RECRUITINGPHASE3
View Study
300 participants
INTERVENTIONAL
Mumbai, India +1 more
Started: Feb 1, 2020

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

NCT01712490ACTIVE NOT RECRUITINGPHASE3
View Study
1.33K participants
INTERVENTIONAL
Birmingham, United States +214 more
Started: Nov 9, 2012

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616RECRUITINGPHASE3
View Study
1.04K participants
INTERVENTIONAL
Stanford, United States +64 more
Started: Apr 14, 2022
Completed Clinical Trials
10 completed trials for ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) in Hodgkin Lymphoma

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

NCT03159897COMPLETEDPHASE3
View Study
500 participants
INTERVENTIONAL
Padua, Italy +45 more
Started: Aug 1, 2017

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

NCT01404936COMPLETEDPHASE2
View Study
35 participants
INTERVENTIONAL
Houston, United States
Started: Jul 1, 1996

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

NCT00002561COMPLETEDPHASE3
View Study
405 participants
INTERVENTIONAL
Calgary, Canada +21 more
Started: Jan 25, 1994

High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

NCT00784537COMPLETEDPHASE2, PHASE3
View Study
520 participants
INTERVENTIONAL
Aviano, Italy +26 more
Started: Sep 1, 2008

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

NCT00369681COMPLETEDPHASE2
View Study
51 participants
INTERVENTIONAL
Duarte, United States +3 more
Started: May 1, 2006

Rituximab and ABVD for Hodgkin's Patients

NCT00504504COMPLETEDPHASE2
View Study
85 participants
INTERVENTIONAL
Houston, United States
Started: Mar 1, 2001

Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NCT07171827COMPLETEDNA
View Study
60 participants
INTERVENTIONAL
Helwan, Egypt
Started: Mar 1, 2023

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

NCT02247869COMPLETEDPHASE2
View Study
100 participants
INTERVENTIONAL
San Giovanni Rotondo, Italy +36 more
Started: Feb 1, 2012

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

NCT01251107COMPLETEDPHASE3
View Study
331 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 1, 2000

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

NCT00654732COMPLETEDPHASE2
View Study
58 participants
INTERVENTIONAL
Miami, United States +3 more
Started: Mar 19, 2008
Showing 20 of 48 total trials